TY - JOUR
T1 - Influence of penetration enhancers on topical delivery of 5-aminolevulinic acid from bioadhesive patches
AU - Morrow, Desmond I. J.
AU - McCarron, P. A.
AU - Woolfson, A. David
AU - Juzenas, Petras
AU - Juzeniene, Asta
AU - Iani, Vladimir
AU - Moan, Johan
AU - Donnelly, Ryan F.
PY - 2010/6
Y1 - 2010/6
N2 - Objectives The inclusion 01 chemical penetration enhancers in a novel patch-based system for the delivery of 5-aminolevulinic acid (ALA) was examined in vitro and in vivo. Poor penetration of ALA has been implicated as the primary factor for low response rates achieved with topical ALA-based photodynamic therapy of thicker neoplastic lesions. such as nodular basal cell carcinomas. Methods Several chemical permeation enhancers (dimethylsulfoxide, Labrafac CC. Labrafac PG and Labrafil M1944CS) were incorporated into bioadhesive patches tailored to deliver 19 mg ALA/cm(2). Key findings In-vitro depth penetration studies into excised porcine skin showed that high concentrations of ALA (>9 mu mol/cm(3)) could be delivered to a depth of 1.875 mm. However, inclusion of permeation enhancers did not significantly increase ALA delivery, relative to the control (P > 0.05). In-vivo studies were in strong agreement with in-vitro results, with formulations containing chemical enhancers showing no improvement in delivery compared with the control. Conclusions The patches designed in this work are suited to defineable ALA delivery without the need to immobilise patients for up to 6 h, as IS common with the cream-under-occlusion approach. Overall, permeation enhancers were not found to markedly enhance the topical delivery of ALA. 11 chemical penetration enhancers may have a greater effect on the delivery of more lipophilic ALA prodrugs, which are thought to primarily permeate the stratum corneum via the intercellular pathway.
AB - Objectives The inclusion 01 chemical penetration enhancers in a novel patch-based system for the delivery of 5-aminolevulinic acid (ALA) was examined in vitro and in vivo. Poor penetration of ALA has been implicated as the primary factor for low response rates achieved with topical ALA-based photodynamic therapy of thicker neoplastic lesions. such as nodular basal cell carcinomas. Methods Several chemical permeation enhancers (dimethylsulfoxide, Labrafac CC. Labrafac PG and Labrafil M1944CS) were incorporated into bioadhesive patches tailored to deliver 19 mg ALA/cm(2). Key findings In-vitro depth penetration studies into excised porcine skin showed that high concentrations of ALA (>9 mu mol/cm(3)) could be delivered to a depth of 1.875 mm. However, inclusion of permeation enhancers did not significantly increase ALA delivery, relative to the control (P > 0.05). In-vivo studies were in strong agreement with in-vitro results, with formulations containing chemical enhancers showing no improvement in delivery compared with the control. Conclusions The patches designed in this work are suited to defineable ALA delivery without the need to immobilise patients for up to 6 h, as IS common with the cream-under-occlusion approach. Overall, permeation enhancers were not found to markedly enhance the topical delivery of ALA. 11 chemical penetration enhancers may have a greater effect on the delivery of more lipophilic ALA prodrugs, which are thought to primarily permeate the stratum corneum via the intercellular pathway.
UR - https://www.scopus.com/pages/publications/77953565911
U2 - 10.1211/jpp/62.06.0004
DO - 10.1211/jpp/62.06.0004
M3 - Article
SN - 2042-7158
VL - 62
SP - 685
EP - 695
JO - JOURNAL OF PHARMACY AND PHARMACOLOGY
JF - JOURNAL OF PHARMACY AND PHARMACOLOGY
IS - 6, Sp.
ER -